On Thursday, the FDA announced the approval of a new drug, Savaysa, to reduce the risk of stroke and blood clots in patients with atrial fibrillation. Savaysa was made by Daiichi Sankyo Co Ltd and, like the other anti-clotting drugs, carries a serious risk of bleeding. It has also been approved to treat deep vein thrombosis and pulmonary embolism in patients who have been previously treated.How does your pharmacy prepare you as a practitioner to counsel patients on newly approved medications?
For additional information please click here
Image courtesy of (cooldesign) / freedigitalphotos.net